Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abiomed Inc (NQ: ABMD )

291.12 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 291.12
Bid (Size) 285.69 (1)
Ask (Size) 330.00 (1)
Prev. Close 291.12
Today's Range 291.12 - 291.12
52wk Range 219.84 - 376.99
Shares Outstanding 45,460,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Abiomed's Impella Shows Heart Function, Symptom Improvements For High-Risk PCI Patients
 
Via Benzinga
Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella
From Abiomed
Via Business Wire

Performance

YTD
-20.52%
-20.52%
1 Month
+10.68%
+10.68%
3 Month
+12.74%
+12.74%
6 Month
-4.46%
-4.46%
1 Year
-10.13%
-10.13%

More News

Read More
Abiomed: Q1 Earnings Insights
Via Benzinga
ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*
From Abiomed, Inc.
Via Business Wire
Recap: Abiomed Q4 Earnings
Via Benzinga
What 4 Analyst Ratings Have To Say About Abiomed
Via Benzinga
Recap: Abiomed Q3 Earnings
Via Benzinga
Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Quant Ratings Updated on 97 Stocks
Via InvestorPlace
Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps
From Abiomed, Inc.
Via Business Wire
Quant Ratings Updated on 85 Stocks
Via InvestorPlace
Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference
From Abiomed, Inc.
Via Business Wire
SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes
From Abiomed
Via Business Wire
Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year
From Abiomed, Inc.
Via Business Wire
A Preview Of Abiomed's Earnings
Via Benzinga
World’s First Patient Implanted with Impella BTR Minimally Invasive Heart Pump
From Abiomed
Via Business Wire
Markets Rise Despite Another New 2-Year High For US 10-Year Treasury Note
Via Benzinga
Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Via Benzinga
First Patient in Japan Treated with Impella 5.5 with SmartAssist
From Abiomed, Inc.
Via Business Wire
7 Medical Device Stocks to Buy as Covid-19 Fears Fade
Via InvestorPlace
Abiomed to Host Investor Call on Impella ECP, the World’s Smallest Heart Pump at 9 French
From Abiomed, Inc.
Via Business Wire
Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference
From Abiomed, Inc.
Via Business Wire
Abiomed's Return On Capital Employed Insights
Via Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.